The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant cells showed weak to moderate cytoplasmic positivity with additional nucleolar staining in many cases. A few cases of malignant melanoma, ovarian, skin, testis, colorectal and liver cancers exhibited strong positivity. Malignant gliomas and thyroid cancers were weakly stained or negative.
Most of the cancer cells displayed weak to moderate cytoplasmic and/or nuclear positivity. Lymphomas along with several breast, prostate, cervical and endometrial cancers were negative.
Squamous cell carcinomas of head and neck cancers and papillary adenocarcinomas of thyroid showed strong membranous and cytoplasmic staining. Several cases of skin, urothelial and renal cancers exhibited moderate to strong positivity. Several cases of gliomas, lymphomas, melanomas, liver and pancreatic cancers displayed moderate to strong cytoplasmic positivity. Remaining malignant tissues were negative.
Validation
One antibody yielding a staining pattern and there is no available gene/protein characterization data or the staining pattern is partly consistent with or contradicted by limited gene/protein characterization data
The multi-targeting antibody yielding a staining pattern partly consistent with limited gene/protein characterization data or there is no available gene/protein characterization data for all or at least one of the genes
The multi-targeting antibody yielding a staining pattern partly consistent with limited gene/protein characterization data or there is no available gene/protein characterization data for all or at least one of the genes
